All patients
subjects at risk
azithromycin in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
RECOVERY (AZI, Horby), 2020 0.97 [0.87; 1.08]
0.98 [0.89 ; 1.08 ] COALITION II Covid-19 Brazil (Furtado), 2020, RECOVERY (AZI, Horby), 2020 2 0% 8,161 moderate not evaluable deathsdetailed results COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.43 [0.13; 1.44]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
RECOVERY (AZI, Horby), 2020 0.97 [0.87; 1.08]
Sekhavati, 2020 0.49 [0.02; 14.80]
0.97 [0.88 ; 1.07 ] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, RECOVERY (AZI, Horby), 2020, Sekhavati, 2020 4 0% 8,603 moderate not evaluable deaths (time to event analysis only)detailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
RECOVERY (AZI, Horby), 2020 0.97 [0.87; 1.08]
0.98 [0.89 ; 1.08 ] COALITION II Covid-19 Brazil (Furtado), 2020, RECOVERY (AZI, Horby), 2020 2 0% 8,161 moderate not evaluable clinical improvementdetailed results COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
0.76 [0.56 ; 1.04 ] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020 2 0% 728 moderate not evaluable clinical improvement (14-day)detailed results COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
0.76 [0.56 ; 1.04 ] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020 2 0% 728 moderate not evaluable clinical improvement (28-day)detailed results COALITION II Covid-19 Brazil (Furtado), 2020 0.70 [0.47; 1.04]
0.70 [0.47 ; 1.04 ] COALITION II Covid-19 Brazil (Furtado), 2020 1 0% 397 NA not evaluable clinical improvement (7-day)detailed results COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.89 [0.59; 1.35]
COALITION II Covid-19 Brazil (Furtado), 2020 0.94 [0.63; 1.40]
0.92 [0.69 ; 1.22 ] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020 2 0% 728 moderate not evaluable death or ventilationdetailed results RECOVERY (AZI, Horby), 2020 0.95 [0.87; 1.03]
0.95 [0.87 ; 1.03 ] RECOVERY (AZI, Horby), 2020 1 0% 7,764 NA not evaluable hospital dischargedetailed results RECOVERY (AZI, Horby), 2020 1.04 [0.98; 1.10]
1.04 [0.98 ; 1.10 ] RECOVERY (AZI, Horby), 2020 1 0% 7,764 NA not evaluable mechanical ventilationdetailed results COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.54 [0.70; 3.37]
RECOVERY (AZI, Horby), 2020 0.92 [0.79; 1.07]
Sekhavati, 2020 0.16 [0.01; 3.19]
1.00 [0.62 ; 1.61 ] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, RECOVERY (AZI, Horby), 2020, Sekhavati, 2020 3 32% 8,206 moderate not evaluable radiologic improvement (14-day)detailed results Rashad A (AZI vs SoC), 2021 1.64 [0.94; 2.88]
1.64 [0.94 ; 2.88 ] Rashad A (AZI vs SoC), 2021 1 0% 206 NA not evaluable ICU admissiondetailed results Sekhavati, 2020 0.25 [0.05; 1.28]
0.25 [0.05 ; 1.28 ] Sekhavati, 2020 1 0% 111 NA not evaluable related SAE (TRSAE)detailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.24 [0.50; 3.11]
1.24 [0.50 ; 3.11 ] COALITION II Covid-19 Brazil (Furtado), 2020 1 0% 439 NA not evaluable serious adverse eventsdetailed results COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.02 [0.20; 5.10]
COALITION II Covid-19 Brazil (Furtado), 2020 1.20 [0.82; 1.77]
1.19 [0.82 ; 1.73 ] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020 2 0% 877 moderate not evaluable adverse eventsdetailed results COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.21 [0.82; 1.78]
1.21 [0.82 ; 1.78 ] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1 0% 438 NA not evaluable arrhythmiadetailed results RECOVERY (AZI, Horby), 2020 0.90 [0.71; 1.15]
Sekhavati, 2020 0.98 [0.02; 50.38]
0.90 [0.71 ; 1.14 ] RECOVERY (AZI, Horby), 2020, Sekhavati, 2020 2 0% 7,874 moderate not evaluable long QTdetailed results COALITION II Covid-19 Brazil (Furtado), 2020 0.90 [0.56; 1.43]
0.90 [0.56 ; 1.43 ] COALITION II Covid-19 Brazil (Furtado), 2020 1 0% 439 NA not evaluable renal impairmentdetailed results COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.35 [0.47; 3.86]
COALITION II Covid-19 Brazil (Furtado), 2020 1.44 [0.99; 2.11]
1.43 [1.00 ; 2.05 ] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020 2 0% 770 moderate not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2025-03-09 16:00 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 619
- roots T: 290